Vanguard Global Advisers
TNGX icon

Vanguard Global Advisers’s Tango Therapeutics TNGX Stock Holding History

Vanguard Global Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
64,254
+8,499
+15% +$210K ﹤0.01% 1260
2026
Q1 		$1.17M Buy
+55,755
New +$776K ﹤0.01% 1548

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Global Advisers's TNGX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Tango Therapeutics (TNGX) stake by 15% in Q2 2026, buying an estimated $210K and bringing the position to 64,254 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Vanguard Global Advisers first reported a position in TNGX in Q1 2026 and has held it in 2 quarters since. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Vanguard Global Advisers held 64,254 shares of Tango Therapeutics worth $2.01M as of Q2 2026.
  • Vanguard Global Advisers bought 8,499 Tango Therapeutics shares in Q2 2026, an estimated $210K.
  • Tango Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1260 holding.
  • Vanguard Global Advisers first reported a position in Tango Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.